Quest Diagnostics INC Form 4 insider transactions

Karthik Kuppusamy, SVP at Quest Diagnostics, reports disposition of shares to cover tax obligations and holdings in a 401(k) plan.

Catherine T. Doherty, EVP at Quest Diagnostics, reports the sale of company stock to cover tax obligations and pursuant to a pre-arranged Rule 10b5-1 sales plan.

Michael J. Deppe, SVP, Corp. Controller & CAO of Quest Diagnostics, reported a transaction involving the disposition of common stock to cover tax withholding obligations from vesting restricted stock units.

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, disposed of 242 shares of common stock to cover tax withholding obligations arising from the vesting of restricted stock units.

Quest Diagnostics CEO James E. Davis disposed of 2,936 shares of common stock on February 19, 2025, to cover tax withholding obligations related to vesting restricted stock units.

CEO James E. Davis reports acquisition of restricted stock units and stock options in Quest Diagnostics.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquisition of restricted stock units and stock options.

Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, reports acquisition of restricted stock units and stock options, along with adjustments to existing holdings.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, reports acquisition of shares and stock options.

SVP of Clinical Solutions at Quest Diagnostics, Kuppusamy Karthik, reports acquisition of restricted stock units and stock options, along with adjustments to existing holdings.

EVP Catherine T. Doherty reports acquisition of restricted stock units and stock options, along with indirect disposition of shares through a company plan.

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, reports acquisition of common stock and stock options.

Michael J. Deppe, SVP, Corp. Controller & CAO of Quest Diagnostics, reports acquisition of stock options and restricted stock units, along with adjustments to common stock holdings.

Director Vicky B. Gregg sold 1,250 shares of Quest Diagnostics Inc. (DGX) at a price of $164.568 on February 5, 2025, leaving her with 16,867 shares.

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, sold 403 shares of common stock at a price of $164.3031 on February 5, 2025.

Director Vicky B. Gregg acquired 72 shares of Quest Diagnostics stock through dividend reinvestment on January 29, 2025.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquiring 35 shares of common stock through a dividend reinvestment plan.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, reports the acquisition and disposal of company stock.

Karthik Kuppusamy, SVP at Quest Diagnostics, reports acquisition and disposal of company stock through dividend reinvestment, stock purchase plan, and 401(k) plan.

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, acquired 4 shares of common stock through a dividend reinvestment plan.

Director Timothy M. Ring reports acquisition of phantom stock units and adjustments to holdings due to dividend reinvestment in Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors.

Director Lassiter Wright III reports acquiring phantom stock units through elective deferrals under Quest Diagnostics' deferred compensation plan.

A Quest Diagnostics executive, Michael E. Prevoznik, sold a significant number of shares after exercising stock options, according to a recent SEC filing.

Catherine T. Doherty, an EVP at Quest Diagnostics, exercised stock options and sold shares on November 27, 2024, according to a recent SEC filing.

Michael J. Deppe, SVP, Corp. Controller & CAO of Quest Diagnostics, exercised stock options and sold shares of common stock on November 6, 2024, according to a Form 4 filing with the SEC.

Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics, sold 1,775 shares of common stock at an average price of $156.9156 on October 28, 2024.

Director Vicky B. Gregg increased her holdings in Quest Diagnostics through a dividend reinvestment plan.

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, reports acquiring shares through a dividend reinvestment plan and a restricted share unit award.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquiring 37 shares of common stock through a dividend reinvestment plan.

SVP of Clinical Solutions at Quest Diagnostics, Karthik Kuppusamy, reports acquisition and disposal of company stock, including dividend reinvestment and stock purchase plan transactions.